Peluntamig (PT-217) is a bispecific antibody targeting DLL3 and CD47. The antibody arms of Peluntamig specifically bind to DLL3 on small cell lung cancer tumor cells while blocking the CD47-SIRPa interaction, thereby effectively stimulating macrophage phagocytosis and inducing NK cell-mediated cytotoxicity. Peluntamig exhibits significant anti-tumor activity against small cell lung cancer and also has favorable safety profiles. Peluntamig can be used in a variety of tumor-related studies including those on small cell lung cancer and L1210 leukemia [1] [2].
In Vivo, Peluntamig (15 mg/kg; i.p.; single injection) combined with cyclophosphamide and 5-fluorouracil produces a highly significant enhancement in % ILS and a 70% cure rate in BDF1 mice with advanced L1210 leukemia[2].
References:
[1]. Corica D A, Bell S D, Zhao L, et al. The Era of Precision Medicine: Advancing Treatment Paradigms for Small Cell Lung Cancer[J]. Cancers, 2025, 17(11): 1847.
[2]. Gale G R, Atkins L M, Schwartz P, et al. Potentiating action of 5-fluorouracil when used in combination with platinum compounds and cyclophosphamide in treatment of advanced L1210 leukemia[J]. Bioinorganic Chemistry, 1978, 8(5): 445-451.
In Vivo, Peluntamig (15 mg/kg; i.p.; single injection) combined with cyclophosphamide and 5-fluorouracil produces a highly significant enhancement in % ILS and a 70% cure rate in BDF1 mice with advanced L1210 leukemia[2].
References:
[1]. Corica D A, Bell S D, Zhao L, et al. The Era of Precision Medicine: Advancing Treatment Paradigms for Small Cell Lung Cancer[J]. Cancers, 2025, 17(11): 1847.
[2]. Gale G R, Atkins L M, Schwartz P, et al. Potentiating action of 5-fluorouracil when used in combination with platinum compounds and cyclophosphamide in treatment of advanced L1210 leukemia[J]. Bioinorganic Chemistry, 1978, 8(5): 445-451.